ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,333.015
1.32%
Brent Oil
82.275
0.37%
Bitcoin
65,967.25
-1.18%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Kymera Therapeutics Inc (KYMR) Share Price

KYMR Kymera Therapeutics Inc

33.29
-1.58 (-4.53%)
After Hours
Last Updated: 21:06:45
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Kymera Therapeutics Inc NASDAQ:KYMR NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -1.58 -4.53 33.29 13.41 43.42 34.87 33.19 34.46 408,446 20:06:45   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Biological Pds,ex Diagnstics 78.59M -146.96M -2.4048 -13.85 2.04B
 Type  Size  Price  Time  Units 
 9 1 32.30 20:07:02 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore KYMR News
14/06/202412:00GLOBEKymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
01/06/202413:00GLOBEKymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
29/05/202412:00GLOBEKymera Therapeutics to Participate in Upcoming June Investor Conferences
23/05/202422:00GLOBEKymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
22/05/202416:20GLOBEKymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
14/05/202415:00GLOBEKymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
08/05/202412:00GLOBEKymera Therapeutics to Participate in Upcoming May Investor Conferences
Period
Draw mode
Data Downloads for KYMR

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Kymera Therapeutics Inc Articles